US Biotech Firm Loses Half Its Value After Chinese Cancer Drug Fails

ArriVent, a US biotech company listed on the New York Stock Exchange, lost nearly half its value on Tuesday. The stock closed down 47% after the company announced that its lung cancer drug, firmonertinib, failed to meet its main goal in a final-stage clinical trial. The drug was originally created by Shanghai Allist Pharmaceuticals, a Chinese company, and licensed to ArriVent for global development. This failure is a major setback for ArriVent and a stark reminder of the high risks in drug development.

For everyday people, this matters because it affects the availability and cost of new cancer treatments. When a drug fails, it delays hope for patients and can lead to higher prices for successful drugs as companies try to recoup losses. It also impacts investors, including retirement funds, that hold biotech stocks. The failure might make US companies more cautious about licensing drugs from China, potentially slowing down the flow of new treatments.

Firmonertinib was designed to treat non-small cell lung cancer (NSCLC) with a specific mutation called EGFR exon 20 insertion. This type of cancer is hard to treat, and the drug was seen as a promising option. The phase 3 trial, the most rigorous testing stage, did not show the expected benefit. ArriVent had high hopes for the drug, but now must reassess its pipeline and strategy.

This event underscores the risks of global biotech partnerships. While China has become a major source of new drug candidates, failures like this can be costly. For patients, it means one less potential treatment. For the industry, it may lead to more careful evaluation of Chinese drugs. Ultimately, it shows that drug development is unpredictable, and success is never guaranteed.